|
|
|
Volumn 51, Issue 5, 2005, Pages 607-611
|
|
Problems in the current target therapy of malignancies
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
ANTINEOPLASTIC AGENT;
ARGLABIN;
AZATHIOPRINE;
BEVACIZUMAB;
CANCER ANTIBODY;
CETUXIMAB;
ERLOTINIB;
GEFITINIB;
IBRITUMOMAB TIUXETAN;
IMATINIB;
IODINE 131 ANTI B1 ANTIBODY;
IODINE-131 ANTI-B1 ANTIBODY;
MONOCLONAL ANTIBODY;
PHTHALAZINE DERIVATIVE;
PIPERAZINE DERIVATIVE;
PYRIDINE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
QUINAZOLINE DERIVATIVE;
QUINOLONE DERIVATIVE;
RITUXIMAB;
SESQUITERPENE;
TIPIFARNIB;
TRASTUZUMAB;
VATALANIB;
ANIMAL;
HUMAN;
NEOPLASM;
REVIEW;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
ANTINEOPLASTIC AGENTS;
AZATHIOPRINE;
HUMANS;
NEOPLASMS;
PHTHALAZINES;
PIPERAZINES;
PYRIDINES;
PYRIMIDINES;
QUINAZOLINES;
QUINOLONES;
SESQUITERPENES;
|
|
EID: 33745153411
PISSN: 05073758
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (3)
|
|
References (27)
|
